

AMENDMENTS TO THE CLAIMS:

Claims 1-5. (Canceled).

Claim 6. (Previously Presented) An immunogenic composition comprising a purified anthrax toxin B moiety in a pharmaceutically acceptable carrier, wherein said B moiety comprises SEQ ID NO:8.

Claims 7-55. (Canceled).

Claim 56. (Previously Presented) A purified anthrax toxin B moiety, wherein said B moiety comprises SEQ ID NO:8.

Claim 57. (Previously Presented) A purified anthrax toxin B moiety, wherein said B moiety comprises SEQ ID NO:10.

Claim 58. (Previously Presented) A purified anthrax toxin B moiety, wherein said B moiety comprises SEQ ID NO:11.

Claim 59. (Previously Presented) A purified anthrax toxin B moiety, wherein said B moiety comprises SEQ ID NO:13.

Claim 60. (Previously Presented) A purified anthrax toxin B moiety, wherein said B moiety comprises SEQ ID NO:16.

Claim 61. (Previously Presented) An immunogenic composition comprising a purified anthrax toxin B moiety in a pharmaceutically acceptable carrier, wherein said B moiety comprises SEQ ID NO:10.

Claim 62. (Previously Presented) An immunogenic composition comprising a purified anthrax toxin B moiety in a pharmaceutically acceptable carrier, wherein said B moiety comprises SEQ ID NO:11.

Claim 63. (Previously Presented) An immunogenic composition comprising a purified anthrax toxin B moiety in a pharmaceutically acceptable carrier, wherein said B moiety comprises SEQ ID NO:13.

Claim 64. (Previously Presented) An immunogenic composition comprising a purified anthrax toxin B moiety in a pharmaceutically acceptable carrier, wherein said B moiety comprises SEQ ID NO:16.

Claims 65-119. (Canceled).